3 completed. 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 3 |
Follow GLPG2222: new trials by email Literature Review of GLPG2222 trials Research Report on GLPG2222
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Assess How Food Affects the Safety and Pharmacokinetics of Galicaftor and Navocaftor Galicaftor, Navocaftor - Healthy Volunteers | Phase 1 | Completed | AbbVie | 24 | 2022-09-27 | 2023-01-17 |
| A Study Looking at the Safety, Tolerability and Efficacy of the Combination of the Study Drugs GLPG2451 and GLPG2222 With or Without GLPG2737 in Patients With Cystic Fibrosis. GLPG2451 dose regimen A, GLPG2451 dose regimen B, GLPG2222 - Cystic Fibrosis | Phase 1 | Completed | Lakefront Biotherapeutics NV | 10 | 2018-05-31 | 2019-04-08 |
| First-in-Human Single and Multiple Dose of GLPG2222 GLPG2222 single dose, Placebo single dose, GLPG2222 multiple doses - Healthy | Phase 1 | Completed | Lakefront Biotherapeutics NV | 40 | 2016-01-01 | 2016-07-29 |
Cystic Fibrosis (1)
Lakefront Biotherapeutics NV (2) · AbbVie (1)
Belgium (2) · Bulgaria (1) · Germany (1) · Greece (1) · Netherlands (1) · Serbia (1) · Sweden (1) · United Kingdom (1) · United States (1)
Kirsteen Donaldson, MD (1) · Olivier Van de Steen, MD MBA (1)
2015 (1), 2017 (1)